Hormone In Vitro Research Only

CJC-1295: Sustained Growth Hormone Release & DAC Technology

6–8 Day Half-Life via DAC Technology

CJC-1295 is a synthetic GHRH analogue modified with Drug Affinity Complex (DAC) technology — a maleimide group that covalently binds albumin in the bloodstream, extending half-life from minutes (native GHRH) to 6–8 days. In a Phase II human clinical trial by Teichman et al., a single injection produced 2–10 fold GH elevation and 1.5–3 fold IGF-1 elevation maintained for 6 days — establishing it as the most studied sustained-release GHRH analogue.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

⚗️

GHRH Receptor Agonism

Binds GHRH-R on pituitary somatotroph cells, stimulating GH gene transcription and secretion through the same pathway as endogenous GHRH.

🧬

DAC Albumin Binding

The maleimide group covalently binds lysine residues on circulating albumin, creating a GH-release depot with a 6–8 day circulating half-life.

🔬

Ipamorelin Synergy

GHRH (CJC-1295) and ghrelin mimetics (ipamorelin) act on different receptors synergistically — together producing GH release far greater than either alone.

📊

IGF-1 Sustained Elevation

Drives sustained hepatic IGF-1 production lasting the full week between injections — enabling consistent downstream anabolic and regenerative signaling.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

⏱️

6–8d

Half-Life (w/DAC)

vs. minutes for native GHRH

📈

2–10×

GH Elevation

Phase II human trial (Teichman 2006)

🧪

1.5–3×

IGF-1 Elevation

Sustained 6 days post-injection

💊

Phase II

Human Safety Data

No serious adverse events reported

GH & IGF-1 Elevation Over Time — CJC-1295 Single Injection (Phase II Human Trial)

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

GH fold-increase over baseline. Source: Teichman et al. (2006) J Clin Endocrinol Metab. PMID 16822960.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

91%

Tolerability

Low Severity

18%

Transient Flushing

Low Severity

14%

Water Retention

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.